Recent advances in postmortem pathology and neurochemistry in schizophrenia

Current Opinion in Psychiatry

Volumn 22, Issue 2, 2009, Pages 154-160

  Dean, Brian ^a,c,d,e   Boer, Simone ^a   Gibbons, Andrew ^a,c   Money, Tammie ^a,c   Scarr, Elizabeth ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b Centre for Neuroscience   (Germany)

^c Department of Psychiatry ^*  (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Postmortem; Review; Schizophrenia

Indexed keywords

MICRORNA;

AUTOPSY; DISC1 GENE; DTNB1 GENE; GENE; HUMAN; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; NRG1 GENE; PROTEOMICS; REVIEW; RGS4 GENE; SCHIZOPHRENIA; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

BRAIN; DNA METHYLATION; ENERGY METABOLISM; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MICRORNAS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; PROMOTER REGIONS, GENETIC; PROTEOME; RISK FACTORS; SCHIZOPHRENIA; SOCIAL ENVIRONMENT;

EID: 62349095315     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328323d52e     Document Type: Review

References (58)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250:274-285.
2. Arion D, Unger T, Lewis DA, et al. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62:711-721. A strategically designed microarray study focused on genes with definable CNS function that suggests a role for altered pro-inflammatory pathways in the CNS of patients with schizophrenia.
3. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res 2007; 32:1749-1756.
4. Haroutunian V, Katsel P, Dracheva S, et al. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 2007; 10:565-573. A significant study that strongly reinforces a role for altered expression of myelin-related genes in the CNS of patients with schizophrenia.
5. Dean B, Keriakous D, Scarr E, Thomas EA. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust NZJ Psychiatry 2007; 41:308-320. An alternate approach to profiling the human transcriptome that identified changes in cell adhesion, signal transduction, development, transcription, energy/metabolism and myelination as being altered in schizophrenia. In addition, preliminary data are presented to suggest that some changes in gene expression may only occur at specific times during the disease progression.
6. McCullumsmith RE, Gupta D, Beneyto M, et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 2007; 90:15-27. A PCR study confirming altered levels of myelin-related mRNA in the CNS of patients with schizophrenia.
7. Mitkus SN, Hyde TM, Vakkalanka R, et al. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophr Res 2008; 98:129-138.
8. Narayan S, Head SR, Gilmartin TJ, et al. Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 2009; 87:278-288. This article shows that differences in gene expression profiles change, in the DLPFC of patients with schizophrenia, as the disease progresses. Both studies show many more changes in gene expression early in the course of frank illness (duration < 5 years) compared with what can be detected later in the disease (duration of illness > 20 years). These data suggest that the underlying pathology of schizophrenia may change with disease progression, and this changing gene expression profile may underpin the change in symptom profile as the disease moves from an acute to chronic form.
9. Narayan S, Tang B, Head SR, et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res doi: 80006-8993(08)01941-0 [pii];10.1016/j.brainres.2008.08.023 [doi] [Epub ahead of print]. This article shows that differences in gene expression profiles change, in the DLPFC of patients with schizophrenia, as the disease progresses. Both studies show many more changes in gene expression early in the course of frank illness (duration < 5 years) compared with what can be detected later in the disease (duration of illness > 20 years). These data suggest that the underlying pathology of schizophrenia may change with disease progression, and this changing gene expression profile may underpin the change in symptom profile as the disease moves from an acute to chronic form.
10. Edgar PF, Schonberger SJ, Dean B, et al. A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol Psychiatry 1999; 4:173-178.
11. Sivagnanasundaram S, Cosset B, Dedova I, et al. Abnormal pathways in the genu of the corpus collosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appli 2007; 1:1291-1305. An informative study of the human proteome in the corpus collosum.
12. Smalla KH, Mikhaylova M, Sahin J, et al. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry 2008; 13:878-896. A significant development in the use of two-dimensional electrophoresis in which synaptic enrichment was completed prior to electrophoresis is used to allow the study of levels of synaptic proteins in human CNS. This study highlights a number of changes in synaptic function as being potentially involved in the pathology of schizophrenia.
13. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10:40-68.
14. Chong VZ, Thompson M, Beltaifa S, et al. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res 2008; 100:270-280. A study that begins to investigate the mechanisms by which NRG1-related pathways may be altered in the CNS of patients with schizophrenia.
15. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9:1415-1423.
16. Leliveld SR, Bader V, Hendriks P, et al. Insolubility of disrupted-in-schizophrenia 1 disrupts oligomer-dependent interactions with nuclear distribution element 1 and is associated with sporadic mental disease. J Neurosci 2008; 28:3839-3845. Initial data to suggest that insoluble DISC1 may be altered in the CNS of patients with schizophrenia. Given the role of insoluble proteins in disease such as Alzheimer's, this could be a significant factor that needs considering with regards to the pathology of the schizophrenia.
17. Kamiya A, Kubo K, Tomoda T, et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 2005; 7:1167-1178.
18. Mimics K, Middleton FA, Stanwood GD, et al. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001; 6:293-301.
19. Bowden NA, Scott RJ, Tooney PA. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 2007; 89:165-168.
20. Gibbons A, Scarr E, McOmish CE, et al. Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia. Aust NZJ Psychiatry 2008; 42:740-745.
21. Erdely HA, Tamminga CA, Roberts RC, Vogel MW. Regional alterations in RGS4 protein in schizophrenia. Synapse 2006; 59:472-479.
22. Lipska BK, Mitkus S, Caruso M, et al. RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Hum Mol Genet 2006; 15:2804-2812.
23. Weickert CS, Rothmond DA, Hyde TM, et al. Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr Res 2008; 98:105-110. Recent meta-analyses suggest that there is strong evidence that DTNBP1 is a susceptibility gene for schizophrenia. Therefore, data showing alterations of the expression of this gene are important in beginning to understand how the gene may confer a predisposition for the disorder and be involved in the genesis of the symptoms of schizophrenia.
24. Guo AY, Sun J, Riley BP, et al. The dystrobrevin-binding protein 1 gene: features and networks. Mol Psychiatry 2009; 14:18-29.
25. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40:827-834.
26. Colantuoni C, Hyde TM, Mitkus S, et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct Funct 2008; 213:255-271.
27. Naylor L, Dean B, Pereira A, et al. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter In human hippocampus. Mol Med 1998; 4:671-674.
28. Severance EG, Yolken RH. Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav 2008; 7:37-45.
29. Bray NJ. Gene expression in the etiology of schizophrenia. Schizophr Bull 2008; 34:412-418.
30. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 (Suppl):245-254.
31. Berezikov E, Cuppen E, Plasterk RH. Approaches to microRNA discovery. Nat Genet 2006; 38 (Suppl):S2-S7.
32. Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008; 82:696-711. A seminal study highlighting the potential role of DNA methylation in the pathology of schizophrenia. DNA methylation can be regulated by environmental factors, so this type of study will inform on how genes and environment may interact to cause changes in gene expression that lead to the symptoms of schizophrenia.
33. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE 2007; 2:e809. A study that is the first to show data to suggest that a change in specific gene promoter methylation corresponds to an appropriate change in the level of the expression of that gene in the CNS of patients with schizophrenia.
34. Ruzicka WB, Zhubi A, Veldic M, et al. Selective epigenetic alteration of layer 1 GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol Psychiatry 2007; 12:385-397. Data to suggest that levels of DNA methyltranferase, an enzyme involved in DNA methylation, are altered in cortical neurons of patients with schizophrenia.
35. Hashimoto T, Arion D, Linger T, et al. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2008; 13:147-161.
36. Perkins DO, Jeffries CD, Jarskog LF, et al. MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8:R27.
37. Beveridge NJ, Tooney PA, Carroll AP, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008; 17:1156-1168.
38. Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med 1977; 7:583-597.
39. Seeman P, Ko F, Jack E, et al. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 2007; 61:303-309. Data to explain the mechanism by which altered dopaminergic activity could be involved in the pathology of schizophrenia.
40. Rahman Z, Schwarz J, Gold SJ, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 2003; 38:941-952.
41. Riederer P, Lange KW, Kornhuber J, Jellinger K. Glutamate receptor antagonism: neurotoxicity, antiakinetic effects, and psychosis. J Neural Transm Suppl 1991; 34:203-210.
42. Schoepp DD, Conn PJ. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 1993; 14:13-20.
43. Beneyto M, Kristiansen LV, Oni-Orisan A, et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007; 32:1888-1902.
44. McCullumsmith RE, Kristiansen LV, Beneyto M, et al. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007; 1127:108-118.
45. Oni-Orisan A, Kristiansen LV, Haroutunian V, et al. Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry 2008; 63:766-775. Data that suggest that changes in glutamate release may be important in the pathology of schizophrenia.
46. Woo TU, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res 2008; 1218:267-277.
47. Lewis DA, Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol 2007; 78:109-131.
48. Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005; 26:131-137.
49. Corti C, Crepaldi L, Mion S, et al. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry 2007; 62:747-755. A significant finding to support the hypothesis that changes in receptor homodimerization may be important in the pathology of schizophrenia.
50. Gonzalez-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452: 93-97. Data supporting the notion that receptor heterodimerization, as well as homodimerization, may be altered in the CNS of patients with schizophrenia.
51. Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007; 12:232-246.
52. Newell KA, Zavitsanou K, Jew SK, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:225-233. Further data to support the argument that changes in the muscarinic M1 receptor, rather than other muscarinic receptors, predominate in the cortex of patients with schizophrenia.
53. Dean B, McLeod M, Keriakous D, et al. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7:1083-1091.
54. Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci 2006; 78:1231-1237.
55. Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119:2-6.
56. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007; 61:1161-1170. The first evidence to suggest that the expression of the muscarinic M4 receptor is altered in the hippocampus of patients with schizophrenia. These data indicated that receptor-region-specific changes In the cholinergic system must contribute to abnormal CNS function in patients with the disorder.
57. Scarr E, Cowie TF, Kanellakis S, et al. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry. DOI: mp200828 [pii];10.1038/mp.2008.28 [doi] [Epub ahead of print] A study that has shown that there is a subset of patients with schizophrenia that can be statistically separated from other patients with schizophrenia based on low levels of cortical muscarinic receptors. This raises the possibility that low levels of cortical muscarinic M1 receptors may be a biomarker for a particular form of schizophrenia.
58. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165:1033-1039.